Brind.

Institutional Investors Adjust Holdings in Jazz Pharmaceuticals Stock

1 report, 1 independent Updated Sat 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Various institutional investors modified their holdings in Jazz Pharmaceuticals PLC during the third quarter, according to filings with the Securities and Exchange Commission. Pinnacle Associates Ltd. trimmed its position by 24.2%, while Bank of New York Mellon Corp lifted its position by 44.5% during the first quarter. Bank of America Corp DE and Boston Trust Walden Corp also increased their stakes in the specialty pharmaceutical company's stock.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The reported changes in institutional ownership reflect shifts in market sentiment regarding Jazz Pharmaceuticals. These large-scale buying and selling activities by major financial firms can influence the market price of the company's shares.

From themarketsdaily.com

Who's involved

  • Jazz PharmaceuticalsSpecialty pharmaceutical company whose stock holdings were adjusted by institutional investors.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Jazz PharmaceuticalsSpeculative

    The market price of Jazz Pharmaceuticals could be affected by the changes in institutional ownership.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped